S48. Biomarker development for ipilimumab and prostate GVAX treatment

Abstract

Methods Our own research over the past years has focused on the clinical efficacy in patients with castration-resistant prostate cancer of the combination of an allogeneic cell linebased vaccine (Prostate GVAX) and an anti-CTLA4 checkpoint inhibitor (ipilimumab) in a Phase-I/II dose escalation/expansion trial. We carried out an extensive immune monitoring… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics